Fujian Haixi Pharmaceuticals plans auditor switch to RSM China from Deloitte

• Fujian Haixi Pharmaceuticals will switch financial reporting to China Accounting Standards for Business Enterprises from its interim report ended June 30, 2026.
• Board will seek shareholder approval at an extraordinary general meeting to replace Deloitte with RSM China as 2026 external auditor.
• RSM’s estimated audit fee is RMB 0.9 million versus Deloitte’s prior cap of HK$ 1.98 million, reflecting lower mainland billing rates.
• Deloitte has not started 2026 audit work; management expects no disruption to the 2026 annual audit timetable.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fujian Haixi Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260715-12245359), on July 15, 2026, and is solely responsible for the information contained therein.